Leukaemia Foundation

Change Your Location:

Pharmaceutical Benefits Advisory Committee (PBAC) July 2016 Meeting

Publish Date: 12/5/2016

Tell the PBAC about your experience with MCL, ALL, CML, CLL, SLL, FL and MF

The Leukaemia Foundation encourages people with an interest in the blood cancers or therapies listed for consideration at the next meeting to tell the PBAC about their experiences of the blood cancers and/or treatments listed.  

Read details of the PBAC’s agenda for the July 2016 meeting or the summary table below.

You can make a submission in several ways:

  • Write a letter

Post the letter to: PBAC Secretariat – MDP 952, Department of Health and Ageing, GPO Box 9848, Canberra ACT 2601

Fax the letter to: 02 6289 4175

Note: Consumer submissions close on 7 June 2016

The PBAC wants to hear your views on the following:

  • How does this condition/disease affect your quality of life?
  • What result would you most like to see from this treatment, i.e., improved side-effects, slowing disease progression, more mobility, other benefits?
  • If you have used or prescribed this new medicine – what was your experience of its beneficial effects?
  • If you have used or prescribed this new medicine – what side-effects or toxicities did you experience or observe?
  • If you haven't used the new medicine yet – what are your expectations of it?
  • If you use other currently available therapies or medicines to manage your condition (or for prescribers – for your patient’s condition) – what are the benefits and/or the challenges?
  • Where did you obtain the information that helped form your views on this treatment?

Blood cancer–related applications that are being considered at the July 2016 meeting

Drug name


What is it about?


Celgene Pty Ltd

This application is a major submission seeking approval for the use of lenalidomide for relapsed or refractory mantle cell lymphoma (MCL).


Amgen Australia Pty Ltd

This is a major submission seeking approval for the listing of this new therapy for the treatment of acute lymphocytic leukaemia (ALL).


Bristol-Myers Squibb Australia Ltd

Dasatinib is already on the PBS for the treatment of chronic myeloid leukaemia (CML). This application is seeking approval for the same continuing script process as for Glivec®(imatinib).


Gilead Sciences Pty Ltd

This is a follow-up submission with additional information to the earlier major submission for this new treatment for chronic lymphocytic leukaemia (CLL) and small lymphocytic lymphoma (SLL).


Gilead Sciences Pty Ltd

This is follow-up submission to the earlier major submission with additional information for this new treatment for follicular lymphoma (FL).


Novartis Pharmaceuticals Australia Pty Ltd

Ruxolitinib is already listed on the PBS for myelofibrosis (MF). This minor application is requesting the listing of a new dose tablet.


Contact for your questions:

Anna Williamson

Head of Research & Advocacy

Email: awilliamson@leukaemia.org.au

Phone: 07 3866 4060 or 0412 008 407

More News